{"id":"dhp107","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL2063823","moleculeType":"Small molecule","molecularWeight":"375.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, DHP107 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.","oneSentence":"DHP107 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:32:31.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07095023","phase":"NA","title":"Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Breast Cancers","enrollment":112},{"nctId":"NCT01839773","phase":"PHASE3","title":"Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer","status":"COMPLETED","sponsor":"Daehwa Pharmaceutical Co., Ltd.","startDate":"2013-03","conditions":"Stage IV Gastric Cancer","enrollment":238},{"nctId":"NCT04675528","phase":"PHASE1","title":"Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study","status":"COMPLETED","sponsor":"Daehwa Pharmaceutical Co., Ltd.","startDate":"2021-05-04","conditions":"Advanced Solid Tumor","enrollment":25},{"nctId":"NCT03326102","phase":"PHASE2","title":"Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Daehwa Pharmaceutical Co., Ltd.","startDate":"2018-07-06","conditions":"Recurrent or Metastatic Breast Cancer","enrollment":72},{"nctId":"NCT02890511","phase":"PHASE1, PHASE2","title":"A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer","status":"COMPLETED","sponsor":"Daehwa Pharmaceutical Co., Ltd.","startDate":"2010-08","conditions":"Solid Tumor, Stage IV Gastric Cancer","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Liporaxel®, Oral Paclitaxel"],"phase":"phase_2","status":"active","brandName":"DHP107","genericName":"DHP107","companyName":"Daehwa Pharmaceutical Co., Ltd.","companyId":"daehwa-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DHP107 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}